Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 3/2018

01-09-2018 | review

Role of complement in the pathogenesis of thrombotic microangiopathies

Authors: Eszter Trojnár, Ágnes Szilágyi, Bálint Mikes, Dorottya Csuka, György Sinkovits, Prof. Zoltán Prohászka

Published in: memo - Magazine of European Medical Oncology | Issue 3/2018

Login to get access

Summary

Thrombotic microangiopathies (TMAs) are rare but life-threatening disorders characterized by microvascular hemolytic anemia and acute thrombocytopenia with or without organ damage. The term TMA covers various subgroups of diseases, the pathogenesis of which is briefly summarized in this review. As highlighted here, complement activation may represent an important amalgamating process in all of these conditions, since it is able to link together activation and damage of multiple involved cell types, such as endothelial cells, platelets, and neutrophils.
Literature
1.
Warwicker P, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int. 1998;53(4):836–44.CrossRefPubMed
2.
Szarvas N, et al. Genetic analysis and functional characterization of novel mutations in a series of patients with atypical hemolytic uremic syndrome. Mol Immunol. 2016;71:10–22.CrossRefPubMed
3.
Caprioli J, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267–79.CrossRefPubMedPubMedCentral
4.
Westra D, et al. Atypical hemolytic uremic syndrome and genetic aberrations in the complement factor H‑related 5 gene. J Hum Genet. 2012;57(7):459–64.CrossRefPubMedPubMedCentral
5.
Jozsi M, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood. 2008;111(3):1512–4.CrossRefPubMed
6.
7.
Thurman JM, et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2009;4(12):1920–4.CrossRefPubMedPubMedCentral
8.
Stahl AL, Sartz L, Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood. 2011;117(20):5503–13.CrossRefPubMed
9.
Westra D, et al. Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome. Pediatr Nephrol. 2017;32(2):297–309.CrossRefPubMed
10.
Orth D, et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol. 2009;182(10):6394–400.CrossRefPubMed
11.
Arvidsson I, et al. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome. J Immunol. 2015;194(5):2309–18.CrossRefPubMed
12.
Morigi M, et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol. 2011;187(1):172–80.CrossRefPubMed
13.
14.
Bettoni S, et al. Interaction between multimeric von Willebrand factor and complement: a fresh look to the pathophysiology of microvascular thrombosis. J Immunol. 2017;199(3):1021–40.CrossRefPubMed
15.
Reti M, et al. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2012;10(5):791–8.CrossRefPubMed
16.
17.
Mikes B, et al. Elevated plasma neutrophil elastase concentration is associated with disease activity in patients with thrombotic thrombocytopenic purpura. Thromb Res. 2014;133(4):616–21.CrossRefPubMed
18.
Ruiz-Torres MP, et al. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost. 2005;93(3):443–52.PubMedCrossRef
19.
Jodele S, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013;122(12):2003–7.CrossRefPubMedPubMedCentral
20.
Gloude NJ, et al. Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD. Blood. 2017;130(10):1259–66.CrossRefPubMedPubMedCentral
21.
Yuen J, et al. NETosing neutrophils activate complement both on their own NETs and bacteria via alternative and non-alternative pathways. Front Immunol. 2016;7:137.CrossRefPubMedPubMedCentral
22.
Farkas P, et al. Complement activation, inflammation and relative ADAMTS13 deficiency in secondary thrombotic microangiopathies. Immunobiology. 2017;222(2):119–27.CrossRefPubMed
23.
Cofiell R, et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood. 2015;125(21):3253–62.CrossRefPubMedPubMedCentral
24.
Azukaitis K, et al. The phenotypic spectrum of nephropathies associated with mutations in diacylglycerol kinase epsilon. J Am Soc Nephrol. 2017;28(10):3066–75.CrossRefPubMedPubMedCentral
25.
26.
Leffler J, et al. Decreased neutrophil extracellular trap degradation in Shiga toxin-associated haemolytic uraemic syndrome. J Innate Immun. 2017;9(1):12–21.CrossRefPubMed
27.
Lukasz A, et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) in patients with Shiga toxin mediated haemolytic uraemic syndrome (STEC-HUS). Thromb Haemost. 2014;111(2):365–72.CrossRefPubMed
28.
Huang DT, et al. T‑antigen activation for prediction of pneumococcus-induced hemolytic uremic syndrome and hemolytic anemia. Pediatr Infect Dis J. 2006;25(7):608–10.CrossRefPubMed
29.
Szilagyi A, et al. The use of a rapid fluorogenic neuraminidase assay to differentiate acute streptococcus pneumoniae-associated hemolytic uremic syndrome (HUS) from other forms of HUS. Clin Chem Lab Med. 2015;53(4):e117–e9.CrossRefPubMed
30.
Mikes B, et al. Carboxiterminal pro-endothelin-1 as an endothelial cell biomarker in thrombotic thrombocytopenic purpura. Thromb Haemost. 2016;115(5):1034–43.CrossRefPubMed
31.
Bettoni G, et al. ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2012;10(8):1556–65.CrossRefPubMed
Metadata
Title
Role of complement in the pathogenesis of thrombotic microangiopathies
Authors
Eszter Trojnár
Ágnes Szilágyi
Bálint Mikes
Dorottya Csuka
György Sinkovits
Prof. Zoltán Prohászka
Publication date
01-09-2018
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 3/2018
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-017-0380-y

Other articles of this Issue 3/2018

memo - Magazine of European Medical Oncology 3/2018 Go to the issue

editorial

Still making progress

comment

My burning issues in the management of liver metastases of advanced colorectal cancer

short review

SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapy

case report

Adenoid cystic carcinoma of the sublingual salivary gland obstructing the submandibular salivary gland duct

review

Thrombotic thrombocytopenic purpura

editorial

Nonmalignant hematology
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits